GLP-1 Side Effects in Women: What to Expect Month One

By HollyHerman.com Wellness Team | Updated May 2026

This article is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs with significant safety considerations. If you are starting a GLP-1 medication, your prescribing clinician is your primary source for personalized guidance. If you experience symptoms that concern you, contact your clinician promptly. If symptoms are severe or you suspect a medical emergency, call 911 or go to the emergency room.

The conversation about GLP-1 medications has been louder on outcomes (“I lost 40 pounds!”) than on what the actual experience of starting one feels like. For women specifically, the first month is a meaningful adjustment period — and going in with realistic expectations is the difference between sticking with the protocol and quitting in week three because you weren't told what would happen.

This is the article I would want my sister, my friend, or a reader to have read before her first injection. Not the marketing version. Not the catastrophizing version either. Just a clear, week-by-week walkthrough of what's likely, what's manageable, and what's serious enough to call your clinician about immediately.

The Side Effect Reality, Up Front

Most women on GLP-1 medications experience some level of side effects, particularly during the first four to six weeks and after each dose increase. The most common effects are gastrointestinal: nausea, decreased appetite (this is the medication working as intended, though it feels strange at first), constipation, occasional diarrhea, stomach discomfort, and sometimes a metallic or “off” taste. Headaches and fatigue are also reported, especially in the first two weeks.

The published clinical trial data on semaglutide (the STEP trials) and tirzepatide (the SURMOUNT trials) showed that the majority of patients experienced at least one gastrointestinal side effect at some point during treatment, but the severity was generally mild to moderate and the effects diminished over time. Discontinuation rates due to side effects in the trials were under 10 percent for most dose levels — meaning the large majority of patients who experienced side effects were able to stay on the medication and continue treatment.

Going in with the expectation that you will probably feel something during the adjustment period — but that those feelings are typically manageable and time-limited — is more realistic than going in expecting either a side-effect-free experience or a debilitating one. Both extremes exist in marketing copy and patient horror stories. The actual median experience is somewhere in the middle.

Week One: The First Injection

Most telehealth platforms including Novi start patients on the lowest available dose. For semaglutide that's typically 0.25 mg weekly. For tirzepatide that's typically 2.5 mg weekly. The starting dose is intentionally low — sometimes called the “starter” or “titration” dose — and is not yet the therapeutic dose for weight management. Its purpose is to allow your body to adjust to the medication before higher doses are introduced.

The injection itself is subcutaneous, typically administered in the abdomen, thigh, or upper arm. Most patients describe the injection as similar to a flu shot or insulin pen — a brief sting, then nothing. The needles are very fine. If you have needle anxiety, the practical reality is usually less dramatic than the anticipation.

In the first 24 to 48 hours after the first injection, most patients notice surprisingly little. The medication has a long half-life (semaglutide is roughly a week, tirzepatide is roughly five days), so the appetite-suppressing effects build over the first several days rather than hitting immediately. By day three to five, most patients notice some change in their hunger pattern — often the first sign is that they're “forgetting to eat” or finishing a meal much earlier than usual.

Mild nausea, if it appears, typically arrives in days four through seven. It's usually most noticeable in the morning or after eating larger meals. Most patients describe it as similar to early-pregnancy nausea or a mild stomach bug — not pleasant, but functional.

Week Two: The Adjustment Period

By week two, most patients have settled into a clearer pattern. Appetite is meaningfully reduced. Meals feel smaller. Foods that previously triggered cravings — particularly hyper-palatable processed foods — often become less appealing. Some patients describe a phenomenon called “food noise” going quiet; the constant background mental chatter about what to eat next, where the next snack is, and what's for dinner becomes much less frequent.

Side effects tend to peak somewhere in the second week for most patients. Nausea may be more frequent. Constipation often appears as food intake drops and fluid intake hasn't been intentionally increased. Some patients experience reflux, particularly if they're eating too quickly or eating greasy foods.

The intervention pattern that helps most: small frequent meals rather than large traditional meals; lean protein at every meal to protect muscle; abundant fluid intake (most patients need to be intentional about this since reduced food means reduced food-source water); avoiding fried, greasy, or very heavy foods that the slowed-gastric-emptying effect makes harder to digest; and adding fiber via vegetables or supplementation to manage constipation.

Caffeine sensitivity sometimes increases in the first weeks. If you're a regular coffee drinker, you may find your usual amount feels too strong. Reducing caffeine slightly during the adjustment period helps some patients with both nausea and sleep quality.

Week Three: Where Most Quitting Happens

Week three is statistically when most patients who don't make it to month three quit. The novelty of “this is different!” has worn off. The side effects, if they're going to be a problem, have been a problem for two solid weeks. The weight on the scale may not yet be moving dramatically. Energy levels are sometimes lower than baseline because food intake has dropped substantially.

This is the week where the support structures matter. A clinician who returns messages quickly. A coaching component (many telehealth platforms including Novi advertise included coaching for this reason). A clear understanding that this part is normal and time-limited.

The biological reality of week three is that your body is still adjusting to the medication and to the meaningful caloric reduction it produces. Energy levels often improve in week four and beyond as adaptation completes. The scale typically begins moving more visibly between weeks two and four, though the pattern is highly individual.

What helps in week three: prioritize sleep (8+ hours if possible), prioritize protein (this is non-negotiable for protecting muscle mass), keep movement gentle but consistent (walking is enough), hydrate aggressively, and maintain communication with your clinician about how you're feeling. If symptoms are severe, the next dose escalation can be delayed — and a competent telehealth platform will support that.

Week Four: First Dose Escalation

For most GLP-1 protocols, week four is when the first dose escalation occurs. Semaglutide typically moves from 0.25 mg to 0.5 mg. Tirzepatide typically moves from 2.5 mg to 5 mg. The dose increase is intended to be the actual therapeutic dose at which weight loss accelerates.

The first 7 to 10 days after a dose increase often replicate a milder version of the first-week side effects. Nausea may return. Appetite may drop further. The body needs another week or two to adjust to the higher dose. This pattern typically repeats with each dose escalation throughout the titration schedule.

Patients who are tolerating treatment well usually notice another step-change in appetite and sometimes in early visible weight loss in the days after the first dose increase. Patients who are struggling may need to stay at the lower dose longer, which is a clinical decision your prescribing clinician makes based on how you're doing.

Considerations Specifically for Women

A few patterns are reported more often by female patients than the published trial data fully captures, partly because some of these are about the interaction of GLP-1 with the menstrual cycle and partly because women in clinical trials weren't always asked.

Cyclical nausea variation. Some women report that nausea feels worse during the luteal phase (the week before menstruation) and improves during the follicular phase. This is consistent with progesterone's known effects on gastric motility. It doesn't change the medication response, but it can change the symptom severity during specific weeks of the cycle.

Menstrual cycle changes. Some women experience changes in menstrual cycle length or flow during weight loss of any cause, including GLP-1 mediated weight loss. Significant weight loss can affect estrogen production and cycle regularity. If your cycle changes substantially, mention it to your clinician — it's usually not concerning but is worth tracking.

Oral contraceptive interaction. This is critical and often missed. GLP-1 medications slow gastric emptying, which can affect oral contraceptive absorption. The clinical guidance is that women using oral contraceptives should add a barrier method during the first four weeks of GLP-1 treatment and during dose escalations. Pregnancy is contraindicated on these medications, so this guidance is not optional advice. If you take an oral contraceptive, confirm the protocol with your prescribing clinician and act accordingly.

Bone density considerations. Rapid weight loss has been associated in some studies with reduced bone mineral density. For women approaching or in menopause when estrogen-related bone loss is already a concern, this is meaningful. Adequate protein intake (the 1.2 to 1.6 grams per kilogram of body weight range), calcium adequacy, vitamin D adequacy, and weight-bearing exercise are protective during weight loss and should be part of the protocol.

Muscle mass. Weight loss without resistance training typically includes meaningful lean muscle loss. For women, this is particularly important because midlife muscle loss compounds the metabolic challenges of weight maintenance after treatment. Strength training during GLP-1 treatment isn't optional if your goal is body composition rather than just scale weight.

For more on what compounded GLP-1 medications actually are and how they work, see my how compounded GLP-1 works piece.

Serious Side Effects That Require Medical Attention

The vast majority of GLP-1 side effects are mild and time-limited. A small minority are serious and need immediate clinical attention. Knowing the difference is part of using these medications safely.

Severe persistent abdominal pain, particularly pain that radiates to the back, is potentially a sign of pancreatitis. Pancreatitis is a rare but serious risk on GLP-1 medications. If this occurs, stop the medication and seek medical attention promptly.

Upper-right abdominal pain, particularly after meals, accompanied by nausea, fever, or jaundice (yellowing of the skin or eyes) is potentially a sign of gallbladder problems. Rapid weight loss of any cause increases gallstone risk, and GLP-1 mediated weight loss is no exception. This warrants prompt clinical evaluation.

Severe hypoglycemia (very low blood sugar) is a particular risk for patients also taking insulin or sulfonylureas for diabetes management. Symptoms include shakiness, sweating, confusion, dizziness, and in severe cases loss of consciousness. If you take other diabetes medications, your prescribing clinician should adjust them when starting GLP-1.

Signs of an allergic reaction including widespread rash, swelling of the face or throat, difficulty breathing, or rapid heart rate require emergency care.

Any swelling, lump, or persistent hoarseness in the neck could potentially indicate thyroid involvement. The FDA boxed warning on GLP-1 medications concerns thyroid C-cell tumors observed in animal studies; the relevance to humans is not fully established but the warning exists for a reason. Patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use these medications at all.

Persistent severe vomiting that prevents fluid intake can lead to dehydration and electrolyte imbalance. If you cannot keep fluids down for more than 24 hours, contact your clinician.

Who Should Not Take GLP-1 Medications

The contraindications and warnings on these medications are firm and exist for clinical reasons. Anyone with personal or family history of medullary thyroid carcinoma should not use these medications. Anyone with Multiple Endocrine Neoplasia syndrome type 2 should not use these medications. Patients with a history of pancreatitis should discuss with a clinician whether GLP-1 therapy is appropriate for their specific situation. Pregnancy and breastfeeding are contraindications. A history of severe gastroparesis is a contraindication. Severe gastrointestinal disease may be a contraindication depending on the specific condition.

A reputable telehealth platform screens for these contraindications during intake and declines to prescribe to patients who don't qualify. If you complete an intake on any platform and your screening flags a contraindication, the platform should issue the medical-eligibility refund and recommend you discuss alternative approaches with your primary care provider. This is the floor of acceptable practice in compounded GLP-1 telehealth, not the ceiling.

What to Tell Your Clinician

If you're starting a GLP-1 program through Novi or any telehealth platform, your intake quiz is the moment to disclose everything. Personal and family thyroid history. Personal pancreatitis history. Current medications including oral contraceptives, insulin, sulfonylureas, and any GI medications. Pregnancy status. Eating disorder history. Severe GI conditions. Mental health history relevant to relationship with food.

The screening exists to protect you. A platform that approves anyone who fills out the form is a platform to be skeptical of. A platform that declines candidates who shouldn't be on these medications and refunds the initial fee is operating responsibly. For a look at how Novi specifically handles eligibility screening and the medical-eligibility refund, see the main Novi review.

The Honest Bottom Line on Side Effects

Most women on GLP-1 medications experience some side effects, particularly during the first month and after each dose increase. The majority of those side effects are gastrointestinal, mild to moderate, and time-limited. A small minority of patients experience side effects severe enough to require dose adjustments or discontinuation. A very small minority experience the rare but serious effects that require immediate clinical attention.

The first month is the hardest. Going in with realistic expectations, a clear understanding of what to manage versus what to call about, and the supporting nutritional and lifestyle structure (protein, hydration, fiber, sleep, resistance training) makes the difference between completing the protocol and quitting in week three.

If you're considering Novi specifically, factor the 3-month commitment into your decision in light of the side effect timeline. The first month is the adjustment period. Months two and three are typically when patients see meaningful weight loss and significantly reduced side effect burden. Quitting in week three before completing the adjustment misses both the clinical benefit and absorbs the financial commitment for treatment you didn't fully receive. Read the cost breakdown for the full commitment math.

For the platform comparison covering Novi against MEDVi, TrimRx, and AgelessRx — including how the support structures during the first-month adjustment period compare across platforms — see my full Novi vs MEDVi vs TrimRx comparison.

Editorial note: This article references the published safety profiles of semaglutide (Wegovy, Ozempic, Rybelsus) and tirzepatide (Zepbound, Mounjaro) as established in the STEP, SUSTAIN, SELECT, SURMOUNT, and SURPASS clinical trials. Compounded semaglutide and compounded tirzepatide are not FDA-approved for safety, effectiveness, or quality. Individual responses to any GLP-1 medication vary based on multiple clinical factors. This article is for informational purposes only and does not constitute medical advice.